LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure.
Lion Biotechnologies, Inc. (the Company) from time to time makes
presentations to analysts, current stockholders and others. A
copy of the Companys presentation is furnished as Exhibit 99.1 to
this current report on Form 8-K and incorporated under this Item
7.01 by reference.
The information contained in this Item 7.01, including Exhibit
99.1, shall not be deemed filed for any purpose, and shall not be
deemed incorporated by reference to any filing under the
Securities Act of 1933, as amended, or the Securities Exchange
Act of 1934, as amended, regardless of any general incorporation
language in any such filing.
| Item 9.01 | Financial Statements And Exhibits |
(d)Exhibits
| Exhibit No. | Description | |
| 99.1 | Lion Biotechnologies, Inc., Corporate Presentation. |
About LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO)
Lion Biotechnologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The Company develops a portfolio of TIL-based products for the treatment of solid tumors. In addition to LN-144, the Company intends to develop additional TIL-based pipeline products to treat a range of solid tumors. It develops LN-145 to treat cervical and head and neck cancers. TIL therapy involves growing a patient’s TIL in special culture conditions outside the patient’s body, or ex vivo, and then infusing the T cells back into the patient in combination with interleukin-2 (IL-2).